ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 17.2 | 14.3 | 13.1 |
| Other income | 1.6 | 0.1 | 0.1 |
| Total income | 18.7 | 14.3 | 13.2 |
| Profit before exceptional items & tax | 1.9 | 0.3 | 1.5 |
| Profit before tax | 1.9 | 0.3 | 1.5 |
| Net profit | 1.1 | 0.2 | 0.9 |
| Operating margin | 10.2% | 2.1% | 11.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +22.20% |
|---|---|
| Net profit, quarter on quarter | +450.00% |
| Revenue, year on year | +31.30% |
| Operating profit, year on year | -78.60% |
| Operating profit, quarter on quarter | +50.00% |
BSE results filing, NSE: VIVOBIOT. Figures extracted from the filing.
Vivo Bio Tech Ltd: key numbers
- Share price
- ₹14.11
- Market cap
- ₹22.76 Cr
- Revenue (annual)
- ₹53.33 Cr
- Net profit (annual)
- ₹-1.71 Cr
- P/E (TTM)
- -8.7×Sector 43.8×
- Promoter holding
- 22.51%-8.11% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivo Bio Tech Ltd
All →Vivo Bio Tech Board Meeting Date
Vivo Bio Tech has scheduled a board meeting for November 11, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 30, 2026. The trading window stays closed until 48 hours after results declaration.
Vivo Bio Tech Other Announcement
The company submitted its periodic shareholding pattern for the quarter ended September 30, 2026, disclosing its promoter and public shareholding as mandated by SEBI.
Vivo Bio Tech Adverse Business Impact
Vivo Bio Tech reports a fire at its Telangana research facility damaging labs, equipment, and samples. No casualties; damage under assessment with adequate insurance coverage in place.
Vivo Bio Tech Other Announcement
Vivo Bio Tech Ltd filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Vivo Bio Tech Management Change
Vivo Bio Tech Limited announced the re-appointment of Sri Kalyan Kompella and Sankaranarayanan Alangudi as Executive Directors, effective November 2026 and January 2027 respectively.
Vivo Bio Tech Annual General Meeting
Vivo Bio Tech Ltd held its 39th Annual General Meeting on September 30, 2026, to adopt financial statements and re-appoint directors.